Serum levels of glial cell line-derived neurotrophic factor as a biomarker for mood disorders and lithium response
Serum levels of glial cell line-derived neurotrophic factor as a biomarker for mood disorders and lithium response
复制标题
DOI：
10.1016/j.psychres.2021.113967
复制
发表时间：
2021-04
影响因子：
11.3
通讯作者：
Keita Idemoto;T. Niitsu;Tatsuki Hata;T. Ishima;S. Yoshida;K. Hattori;Tadasu Horai;Ikuo Otsuka;H. Yamamori;S. Toda;Yosuke Kameno;K. Ota;Y. Oda;Atsushi Kimura;T. Hashimoto;N. Mori;M. Kikuchi;Y. Minabe;R. Hashimoto;A. Hishimoto;K. Nakagome;K. Hashimoto;M. Iyo
中科院分区：
文献类型：
--
作者：
Keita Idemoto;T. Niitsu;Tatsuki Hata;T. Ishima;S. Yoshida;K. Hattori;Tadasu Horai;Ikuo Otsuka;H. Yamamori;S. Toda;Yosuke Kameno;K. Ota;Y. Oda;Atsushi Kimura;T. Hashimoto;N. Mori;M. Kikuchi;Y. Minabe;R. Hashimoto;A. Hishimoto;K. Nakagome;K. Hashimoto;M. Iyo
胶质细胞源性神经营养因子（GDNF）在神经精神疾病的病理生理中起着重要作用。我们检测了双相情感障碍（BD）和重性抑郁症（MDD）患者血清GDNF水平及其与锂治疗反应的关系。我们采用多中心（6个研究中心）、探索性、横断面病例对照设计，招募了448名受试者：143名BD患者、116名MDD患者和158名健康对照（HC）。我们使用临床总体印象（CGI）评估患者的临床严重程度，并使用Alda量表评估锂治疗的反应。BD组和MDD组血清GDNF水平均显著低于HC组，BD组和MDD组间差异无统计学意义。校正后，BD和MDD患者缓解或抑郁状态下的血清GDNF水平与HC值相比有所下降。BD患者血清GDNF水平较低与CGI和Alda评分较高相关（即，严重疾病和对锂治疗的良好反应）。我们的研究结果表明，血清GDNF水平可能是BD和MDD缓解或抑郁状态的生物标志物。血清GDNF水平可能与BD患者锂盐反应有关。
Glial cell line-derived neurotrophic factor (GDNF) plays an important role in the pathophysiology of neuropsychiatric disorders. We examined serum GDNF levels in bipolar disorder (BD) patients and major depressive disorder (MDD) patients and their association with response to lithium therapy. We used a multicenter (six sites), exploratory, cross-sectional case-control design and recruited 448 subjects: 143 BD patients, 116 MDD patients, and 158 healthy controls (HCs). We evaluated the patients' clinical severity using the Clinical Global Impression (CGI), and responses to lithium therapy using the Alda scale. The serum GDNF levels were significantly decreased in the BD and MDD groups compared to the HCs, with no significant difference between the BD and MDD groups. After adjustment, the serum GDNF levels in the BD and MDD patients in remission or depressive states were decreased compared to the HC values. Lower serum GDNF levels in BD patients were associated with higher CGI and Alda scores (i.e., severe illness and good response to lithium therapy, respectively). Our findings suggest that the serum GDNF level may be a biomarker for both BD and MDD in remission or depressive states. The serum GDNF level may be associated with the lithium response of BD patients.